Recent Updates — SBFM

Dr. Steve N. Slilaty, holding approximately 90% of voting power as CEO, approved a written consent to issue more than 20% of outstanding common stock at a deemed discount to the Nasdaq minimum price following a public offering that closed on October 9, 2026. The consent also authorized adjustments to Series D Warrant exercise prices and voluntary adjustments under warrant terms. This action bypasses standard shareholder voting requirements due to concentrated ownership. Sunshine Biopharma Inc. operates in the biotechnology industry.

Sunshine Biopharma Inc. closed a best-efforts public offering on October 9, 2026, raising approximately $6 million in gross proceeds. The company sold 10,509,082 common units at $0.55 per unit and 400,000 pre-funded units at $0.54999 per unit. Each unit includes two Series D warrants exercisable at $0.66 per share, which could generate an additional $14.4 million if fully exercised. Net proceeds will be used for general corporate purposes and working capital. Aegis Capital Corp. acted as the exclusive placement agent.

On July 20, 2026, Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. to sell up to $4,000,000 of common stock. Aegis Capital Corp. will act as the exclusive sales agent and receive a commission of 3.0% of the gross proceeds. The shares will be issued under a shelf registration statement on Form S-3. Sunshine Biopharma Inc. is a biopharmaceutical company.

Sunshine Biopharma Inc. entered into a Release Agreement with Malek Chamoun, the former president of Nora Pharma Inc., a wholly-owned subsidiary, on July 8, 2026, to settle a dispute. The company agreed to pay CAD$1,500,000 (approximately US$1,058,565) in full and final settlement. Sunshine Biopharma Inc. operates in the biopharma industry and develops products for ocular-related diseases.